Should patients with chronic hepatitis C infection be transplanted?

Transplantation Proceedings

Volumn 36, Issue 5, 2004, Pages 1449-1454

  Botero, R C ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ARTICLE; BLOOD TRANSFUSION; DEPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PATIENT SELECTION; TREATMENT OUTCOME; UNITED STATES;

EID: 3142602730     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.06.003     Document Type: Article

References (91)

1. Prince A. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet. 2:1974;241
2. Lindebach B., Rice C.M. Flaviviridae the viruses and their replication. Knipe D., Howley P.M. Fields Virology. 2001;Lipincott Williams & Wilkins, Philadelphia
3. Martell M., et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes quasispecies nature of HCV genome distribution. J Virol. 66:(5):1992;3225-3229
4. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus quasispecies and genotypes. Semin Liver Dis. 15:1995;41
5. Farci P., Purcell R.H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis. 20:2000;103
6. Feinstone S.M., et al. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 292:1975;767
7. Armstrong G.L., et al. The past incidence of hepatitis C virus infection implications for the future burden of chronic liver disease in the United States. Hepatology. 31:2000;777
8. Di Bisceglie A.M., Carithers R.L. Jr, Gores G.J. Hepatocellular carcinoma. Hepatology. 28:1998;1161
9. Di Bisceglie A.M., et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 14:1991;969
10. Alter M.J. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis. 2:1993;155
11. Barrera J.M., et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 21:1995;639
12. Yousuf M., et al. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol. 27:1992;812
13. Alter M.J., et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 327:1992;1899
14. Alter H.J. To C or not to C these are the questions. Blood. 85:1995;1681
15. Gerlach J.T., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 117:1999;933
16. Lechner F., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 191:2000;1499
17. Alter M.J., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 341:1999;556
18. Craxi A., Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis. 23:(Suppl 1):2003;35
19. Rakela J., Vargas H. Hepatitis CV magnitude of the problem. Liver Transplantation. 8:2003;S3
20. Lechmann M., Liang T.J. Vaccine development for hepatitis C. Semin Liver Dis. 20:2000;211
21. Martin P., Friedman L.S. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int. 47:1995;1231
22. Fabrizi F., et al. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients clinical perspectives. Int J Artif Organs. 23:2000;805
23. Bukh J., et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis. 168:1993;1343
24. Fabrizi F., Poordad F.F., Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 36:2002;3
25. Botero R., Sirutis D., Sierra F. Seroprevalence of HCV Infection in high risk groups in Colombia. Acta Medica Colombiana. 17:1992;301
26. Prevention CfDCa Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb Mort Weekly Report. 50:2001;1
27. Muller G.Y., et al. Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int. 41:1992;1055
28. Mondelli M.U., et al. High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second generation assay. Nephron. 61:1992;350
29. Pereira B.J., et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 327:1992;910
30. Roth D. Hepatitis C virus infection and the renal allograft recipient. Nephron. 71:1995;249
31. Zucker K., et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation. 57:1994;832
32. Genesca J., et al. Hepatitis C virus infection in renal transplant recipients epidemiology, clinical impact, serological confirmation and viral replication. J Hepatol. 22:1995;272
33. Kliem V., et al. The long-term course of hepatitis C after kidney transplantation. Transplantation. 62:1996;1417
34. Roth D., et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation. 61:1996;886
35. Vosnides G. Hepatitis C in renal transplantation. Kidney Int. 52:1997;843
36. Mathurin P., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 29:1999;257
37. Hanafusa T., et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 66:1998;471
38. Legendre C., et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 65:1998;667
39. Delladetsima J.K., et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg. 5:1999;294
40. Lam P.W., et al. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 61:1996;378
41. Zyleberg H., Carnot F., Mamzer M., et al. HCV-related fibrosing cholestatic hepatitis. Transplantation. 63:1997;158
42. Davda R., et al. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis. 22:1993;452
43. Johnson R.J., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 328:1993;465
44. Rollino C., et al. Hepatitis C virus infection and membranous glomerulonephritis. Nephron. 59:1991;319
45. Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron. 71:1995;386
46. D'Amico G., et al. Renal involvement in essential mixed cryoglobulinemia. Kidney Int. 35:1989;1004
47. Morales J.M. Hepatitis C and renal transplantation outcome of patients. Nephrol Dial Transplant. 10:(Suppl 6):1995;125
48. Pereira B.J., et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 325:1991;454
49. Zylerberg H., Carnot F., Mamzer M., et al. HCV-related fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 63:1997;158
50. Chan T.M., et al. Clinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation. Nephron. 71:1995;213
51. Ok E., et al. Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Nephrol Dial Transplant. 13:1998;3103
52. Terrault N.A., Wright T.L. Hepatitis C virus in the setting of transplantation. Semin Liver Dis. 15:1995;92
53. Martin P., et al. Histopathological features of hepatitis C in renal transplant candidates (see comment). Transplantation. 69:2000;1479
54. Poterucha J.J., et al. Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction. Hepatology. 15:1992;42
55. Schneeberger P.M., et al. Hepatitis C virus infections in dialysis centers in The Netherlands a national survey by serological and molecular methods. J Clin Microbiol. 36:1998;1711
56. Dalekos G.N., et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant. 13:1998;1804
57. Pawlotsky J.M. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis. 7:2003;127
58. Widell A., et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation. 60:1995;642
59. Zdilar D., et al. Hepatitis C, interferon alfa, and depression. Hepatology. 31:2000;1207
60. Koenig P., et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 45:1994;1507
61. Bruchfeld A., et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 18:2003;1573
62. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation new insights. Nephrol Dial Transplant. 15:(Suppl 8):2000;74
63. Gupta S.K., et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol. 42:2002;1109
64. Martin P., Mitra S., Farrington K., et al. Pegylated (40KDA) interferon alfa-2a (Pegasys) is unaffected by renal impairment. Hepatology. 32:2000;842
65. Zervos X.A., et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 65:1998;1044
66. Singh N., et al. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus association with rejection and increased immunosuppression after transplantation. Surgery. 119:1996;452
67. Rosen H., Shackleton C., Higa L., et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 92:1997;1453
68. Platz K.P., et al. Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant Proc. 30:1998;2232
69. Nelson D., Soldevila-Pico C., Lauwers G., et al. The effect of anti-IL-2R therapy on the course of hepatitis C recurrence after liver transplantation. Hepatology. 32:2000;184
70. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection a perspective on long-term outcome. Semin Liver Dis. 20:2000;17
71. Craxi A., Licata A. Clinical trials results of peginterferons in combination with ribavirin. Seminars in Liver Disease. 23:(Suppl 1):2003;35
72. Feray C., et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest. 89:1992;1361
73. Ghobrial R., Farmer D.G., Baquerizo A., et al. Orthotopic liver transplantation for hepatitis c outcome, effect of immunosupression and causes of retransplantation during and eight year single center experience. Ann Surg. 6:1994;824
74. Casavilla F.A., et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg. 4:1996;448
75. Garcia-Retortillo M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 35:2002;680
76. Gane E.J., et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 110:1996;167
77. McCaughan G.W., Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl. 8:(Suppl 1):2002;S7
78. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 8:(Suppl 1):2002;S14
79. Lau J.Y., et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology. 102:1992;956
80. Rakela J., Vargas H.E. Hepatitis C magnitude of the problem. Liver Transpl. 8:(Suppl 1):2002;S3
81. Ghobrial R.M. Retransplantation for recurrent hepatitis C. Liver Transpl. 8:(Suppl 1):2002;S38
82. Berenguer M., Wright T.L. Treatment strategies for hepatitis C intervention prior to liver transplant, pre-emptively or after established disease. Clin Liver Dis. 7:2003;631
83. Mazzaferro V., Tagger A., Schiavo M., et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc. 33:2001;1355
84. Neff G., Montalbano M., Ozden N., et al. Preliminary treatment results of Pegylated interferon alpha 2b and ribavirin in liver transplant recipients with recurrent hepatitis C virus non responsive to interferon alpha2b and ribavirin. J Hepatology. 38:2003;160
85. Pirsch J., Beltzer F.O. Transmission of HCV by organ transplantation. N Engl J Med. 326:1992;410
86. Eggen B., Nordbo S.A. Transmission of HCV by organ transplantation. N Engl J Med. 326:1992;411
87. Locasciulli A., et al. Hepatitis C virus infection in patients undergoing allogeneic bone marrow transplantation. Transplantation. 52:1991;315
88. Honaker M.R., et al. Impact of hepatitis C virus status in pancreas transplantation a case controlled study. Clin Transplant. 16:2002;243
89. Lim H.L., et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology. 106:1994;248
90. Frickhofen N., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 83:1994;1998
91. Cotler S., Jensen D.M., Kesten S. Hepatitis C virus infection and lung transplantation a survey of practices. Lung Transplant. 18:1999;456